Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04315233 · ClinicalTrials.gov registry record · Phase 1
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
A Phase 1 study of Metastatic Breast Cancer and Recurrent Ovarian Carcinoma, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 2
- Study locations
NCT04315233 is a Phase 1 study of Metastatic Breast Cancer and Recurrent Ovarian Carcinoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 34 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04315233, a Phase 1 study of Metastatic Breast Cancer and Recurrent Ovarian Carcinoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients diagnosed with triple-negative breast cancer.
Conditions Studied
Interventions
- DRUG Ribociclib
- DRUG Belinostat
Study Locations (2)
Utah
- Huntsman Cancer Institute - Salt Lake City
Virginia
- Inova Schar Cancer Institute - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04315233
The ClinicalTrials.gov registry entry for NCT04315233 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (83% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ribociclib is the first listed.
NCT04315233 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Utah, Virginia.
Frequently Asked Questions
What is clinical trial NCT04315233 about?
NCT04315233 is a clinical study titled "Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics". This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients ...
What is the current status of trial NCT04315233?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2021-05-03. Estimated completion is 2026-08.
What conditions does trial NCT04315233 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Recurrent Ovarian Carcinoma.
What interventions are being tested in trial NCT04315233?
The interventions under investigation include: Ribociclib (DRUG), Belinostat (DRUG).
Who is sponsoring clinical trial NCT04315233?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04315233 being conducted?
This trial has 2 study locations across Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.